Tag:
Abilify
Latest Headlines
Latest Headlines
Lundbeck banks on pipeline as antidepressant sales skid
Lundbeck's CFO Anders Gotzsche emphasized the prospects of drugs such as Selincro for alcohol dependence, the experimental antidepressant Lu AA21004 in late-stage development and a long-lasting formulation of Abilify.
Bristol-Myers' Q4 shows growth in newer products
Bristol-Myers Squibb's ( $BMY ) earnings didn't reach the Wall Street goalposts, partly because of higher costs, some of them attributed to U.S. healthcare reforms. Sales of its flagship drug,...
Alexza layoffs looming
Alexza Pharmaceuticals may be literally going for broke as it pursues approval of its inhaled fast-acting antipsychotic drug Adasuve. The company ($ALXA) announced that it will pursue significant,
Two brain receptors may point way to better antipsychotic drugs
The way to more effective schizophrenia treatments may come to this: Researchers have deduced the cell-signaling pattern created by antipsychotic drugs in two brain receptors. The findings, detailed
FDA accepts Otsuka's app for long-lasting Abilify
Otsuka Pharmaceutical has taken an important step forward in the development of a once-monthly version of its blockbuster schizophrenia drug Abilify (aripiprazole). U.S. regulators have accepted for...
Antipsychotics, ADHD meds fuel rising psych-drug use
With sales figures showing that individual psych meds are among Big Pharma's best sellers--think Eli Lilly's ( $LLY ) Zyprexa , for one--it's no surprise to see the percentage of Americans using drugs
Yervoy hits the market with $95M bang
Market watchers expected Bristol-Myers Squibb's ($BMY) new cancer drug to be big, but this fast? The company's second-quarter sales left Wall Street estimates in the dust and prompted an increase in
FDA cites BMS on PR plant offenses
In yet another crackdown on manufacturing violations, the FDA has cited Bristol-Myers Squibb for repeated problems at a plant in Puerto Rico. The plant makes at least eight products, including
Otsuka puts off broadening use of Abilify
Otsuka Pharmaceutical yanked its European application for broader use of Abilify; it had asked the EMEA for permission to market the antipsychotic drug as a treatment for depression. Report
Bristol cuts Abilify sales force by 25%
The pharma sales rep bloodbath continues. Bristol-Myers Squibb has axed one-fourth of the sales force for its antipsychotic drug Abilify. The company won't specify exactly how many jobs were cut.
